Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The presence of an increased number of research and development activities and the presence of a promising product pipeline
4.1.2. Restraints:
4.1.2.1. The onset of side effects
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter’s Five Forces Analysis
5.2 Regulatory Analysis
5.3 Supply Chain Analysis
5.4 Pricing Analysis
5.5 Unmet Needs
6. By Drug type
6.1. Introduction
6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
6.1.2. Market Attractiveness Index, By Drug type Segment
6.2. Anticonvulsants
6.2.1.1. Introduction
6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
6.3. Tricyclic antidepressants
6.4. Local anesthetics
6.5. Antimicrobials
6.6. Hormone creams
6.7. Nerve blocks
6.8. Others
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User Segment
7.2. Hospital pharmacies
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Retail pharmacies
7.4. Online pharmacies
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. Australia
8.5.5.5. Rest of Asia Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape
9.1. Key Developments and Strategies
9.2. Company Share Analysis
9.3. Drug types Benchmarking
9.4. List of Key Companies to Watch
10. Company Profiles
10.1 Allergan
10.1.1 Company Overview
10.1.2 Product Portfolio and Description
10.1.3 Key Highlights
10.1.4 Financial Overview
10.2 Janssen Pharmaceuticals (Johnson and Johnson)
10.3 GTO Pharmaceutical, LLC
10.4 Ipsen Pharma
10.5 Pfizer Inc
LIST NOT EXHAUSTIVE
11. Global Vulvodynia Treatment Market – DataM
11.1. Appendix
11.2. About Us and Distribution Channel
11.3. Contact Us